FDA nod for Boehringer/Lilly’s once-daily diabetes combo
US regulators have cleared the use of a once-daily formulation of Boehringer Ingelheim and Eli Lilly’s diabetes drug Synjardy.
Read More
Tag: Synjardy XR
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
